Endonovo Therapeutics (OTCMKTS:ENDV) versus Quantum Biopharma (NASDAQ:QNTM) Head-To-Head Analysis

Endonovo Therapeutics (OTCMKTS:ENDV) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Insider & Institutional Ownership

1.2% of Quantum Biopharma shares are held by institutional investors. 5.6% of Endonovo Therapeutics shares are held by insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Endonovo Therapeutics and Quantum Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Endonovo Therapeutics	N/A	N/A	N/A
Quantum Biopharma	N/A	-436.23%	-150.85%

Risk and Volatility

Endonovo Therapeutics has a beta of -1.18, meaning that its share price is 218% less volatile than the S&P 500. Comparatively, Quantum Biopharma has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500.

Earnings & Valuation

This table compares Endonovo Therapeutics and Quantum Biopharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Endonovo Therapeutics	$10,000.00	0.00	-$2.18 million	N/A	N/A
Quantum Biopharma	N/A	N/A	-$26.17 million	($8.72)	-0.35

Endonovo Therapeutics has higher revenue and earnings than Quantum Biopharma.

Analyst Recommendations

This is a summary of current ratings and target prices for Endonovo Therapeutics and Quantum Biopharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Endonovo Therapeutics	0	0	0	0	0.00
Quantum Biopharma	1	0	0	0	1.00

Given Endonovo Therapeutics’ higher possible upside, analysts plainly believe Endonovo Therapeutics is more favorable than Quantum Biopharma.

Summary

Endonovo Therapeutics beats Quantum Biopharma on 5 of the 9 factors compared between the two stocks.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.